DEF 14A: Pacira BioSciences Aims for Growth in 2025 with Strategic Realignment

Pacira BioSciences outlines its strategic focus for 2024, positioning itself for significant growth in 2025 and beyond by reshaping its executive team, reallocating resources, and prioritizing investments.

Summary

• Pacira BioSciences is focusing on expanding its position as the Therapeutic Area Leader in opioid-sparing postsurgical pain management.
• 2024 will be a key setup year to drive significant and sustainable growth in 2025 and beyond.
• The company is reshaping its executive team and reallocating resources to the U.S. market.
• Investments are being reprioritized to focus on the start of the NOPAIN Act and operational excellence.
• EXPAREL has treated more than 14 million patients and continues to drive profitability.
• The company expects EXPAREL for lower extremity nerve blocks to grow into a $100 million annual opportunity over time.
• NOPAIN mandates separate CMS reimbursement of non-opioid therapies for postsurgical pain relief across all outpatient settings beginning in January 2025.
• Pacira aims to grow EXPAREL to blockbuster status by advancing key growth drivers in 2024 and beyond.
• These drivers include launching EXPAREL in two new lower extremity nerve block indications, preparing for the rollout of NOPAIN in 2025, and expanding patient access to EXPAREL through 340B drug program pricing and new group purchasing organization partnerships.

Sentiment

Score: 8

Explanation: The document expresses a positive outlook for Pacira's future, driven by strategic initiatives and market opportunities. The focus on growth, innovation, and patient care contributes to a favorable sentiment.

Positives

• EXPAREL has treated over 14 million patients, indicating strong market acceptance.
• Regulatory approvals for lower extremity nerve blocks create a $100 million annual opportunity.
• The NOPAIN Act will drive increased utilization of non-opioid pain management options.
• The company has a commercial portfolio of three best-in-class opioid-sparing products.
• Pacira has a strong presence in total knee arthroplasty (TKA), where anesthesiologists are already performing adductor canal blocks with bupivacaine.

Negatives

• The company has a very limited presence in other lower extremity procedures, such as anterior cruciate ligament (ACL) repair or foot and ankle procedures, which may slow uptake in these segments.
• Net product sales growth fell short of internal targets, and as a result, the Compensation Committee reduced the payout under the annual incentive bonus plan.

Risks

• Uptake in lower extremity procedures, such as ACL repair or foot and ankle procedures, is expected to be slower due to limited presence in these segments.
• The company faces financial pressures facing healthcare systems that further incentivize cost-driven approaches.

Future Outlook

Pacira anticipates significant and sustainable growth in 2025 and beyond, driven by EXPAREL's expansion into new indications, the rollout of the NOPAIN Act, and increased patient access through strategic partnerships.

Management Comments

• Frank D. Lee, Chief Executive Officer: 'I am honored to take the helm at Pacira in order to advance our mission and fulfill the pressing need for safe and effective opioid-sparing pain management solutions.'
• Frank D. Lee, Chief Executive Officer: 'This is a special company that I am humbled and honored to lead through its next phase of growth.'

Industry Context

This announcement reflects the growing trend in the healthcare industry towards non-opioid pain management solutions, driven by concerns about opioid addiction and the desire for safer, more effective pain relief options.

Comparison to Industry Standards

• Pacira's EXPAREL competes with traditional local anesthetics like bupivacaine, but offers the advantage of extended-release, potentially reducing the need for opioids.
• ZILRETTA competes with other intra-articular corticosteroid injections for osteoarthritis knee pain, but is the first and only extended-release option.
• Companies like Heron Therapeutics (HTX) are also developing non-opioid pain management solutions, but Pacira has a broader portfolio of products.
• The NOPAIN Act is expected to benefit companies like Pacira that offer non-opioid alternatives, as it removes cost barriers to their adoption.

Management Changes

Corporate Governance

Related Party Transactions

• David Stack, former CEO, entered into a Transition and Retirement Agreement, providing continued salary, bonus eligibility, equity vesting, and health benefits through September 1, 2024.
• David Stack will provide transition services under a Consulting Agreement from September 1, 2024, to August 31, 2025, receiving $20,000 per month for up to 15 hours of service.

Stakeholder Impact

• Shareholders: The company aims to build shareholder value through commercial growth and strategic initiatives.
• Patients: The company is committed to providing non-opioid pain management solutions to improve patient outcomes.
• Employees: The company is focused on fostering a positive corporate culture and investing in employee development.

Next Steps

• Launch EXPAREL in two new lower extremity nerve block indications.
• Prepare for the rollout of NOPAIN in 2025.
• Expand patient access to EXPAREL through 340B drug program pricing and new group purchasing organization partnerships.

Key Dates

Keywords

EXPAREL, NOPAIN Act, opioid-sparing, pain management, ZILRETTA, iovera, Pacira BioSciences, nerve blocks, reimbursement, postsurgical pain